PMID- 32956155
OWN - NLM
STAT- MEDLINE
DCOM- 20211227
LR  - 20230927
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 28
IP  - 1
DP  - 2022 Jan 1
TI  - Progressive Bone Destruction in Rapidly Destructive Coxopathy Is Characterized by 
      Elevated Serum Levels of Matrix Metalloprotease-3 and C-Reactive Protein.
PG  - e44-e48
LID - 10.1097/RHU.0000000000001578 [doi]
AB  - OBJECTIVE: Rapidly destructive coxopathy (RDC) is a rare condition characterized 
      by rapid joint space narrowing; however, its pathology remains unclear. This 
      study aimed to clarify the association of laboratory biomarkers with the 
      radiological progression of RDC. METHODS: We examined 34 female and 4 male 
      patients with RDC between October 2010 and April 2018. Patients were divided into 
      3 groups according to the progressive radiographic staging of RDC. Group 1 
      patients had progressive obliteration of the joint space without subchondral 
      destruction (n = 11), group 2 had progressed subchondral destruction (n = 18), 
      and group 3 had cessation of bone destruction observed for more than 6 months (n 
      = 9). Clinical evaluation results were assessed using the Japanese Orthopedic 
      Association hip score. Blood test results, including serum matrix 
      metalloproteinase-3 (MMP-3), and C-reactive protein (CRP), were also evaluated. 
      RESULTS: There were no significant differences in patient background or Japanese 
      Orthopedic Association hip scores among the groups. However, there were 
      significant differences in MMP-3 levels among groups, with MMP-3 levels in group 
      2 being significantly higher than those in group 3 (group 2, 118.4 +/- 81.2 ng/mL; 
      group 3, 42.5 +/- 15.1 ng/mL, p < 0.001). The CRP levels in group 2 were also 
      significantly higher than those in group 3 (group 2, 0.77 +/- 0.92 mg/dL; group 3, 
      0.13 +/- 0.07 mg/dL, p = 0.019), but elevated CRP levels in group 2 decreased back 
      to the reference range. CONCLUSIONS: Matrix metalloproteinase-3 and CRP are the 
      biomarkers of RDC progression but not of its occurrence. Severe inflammatory 
      response may be associated with bone destruction in RDC.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ando, Wataru
AU  - Ando W
FAU - Hashimoto, Yoshichika
AU  - Hashimoto Y
AD  - From the Department of Orthopaedic Surgery, Kansai Rosai Hospital, Amagasaki.
FAU - Yasui, Hirohiko
AU  - Yasui H
AD  - From the Department of Orthopaedic Surgery, Kansai Rosai Hospital, Amagasaki.
FAU - Ogawa, Takeshi
AU  - Ogawa T
AD  - From the Department of Orthopaedic Surgery, Kansai Rosai Hospital, Amagasaki.
FAU - Koyama, Tsuyoshi
AU  - Koyama T
AD  - From the Department of Orthopaedic Surgery, Kansai Rosai Hospital, Amagasaki.
FAU - Tsuda, Takayuki
AU  - Tsuda T
AD  - From the Department of Orthopaedic Surgery, Kansai Rosai Hospital, Amagasaki.
FAU - Ohzono, Kenji
AU  - Ohzono K
AD  - Department of Orthopaedic Surgery, Hip Joint Center, Amagasaki Chuo Hospital, 
      Amagasaki, Japan.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Biomarkers)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Biomarkers/blood
MH  - *C-Reactive Protein/analysis
MH  - Female
MH  - Humans
MH  - *Joint Diseases
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Radiography
COIS- The authors declare no conflict of interest.
EDAT- 2020/09/22 06:00
MHDA- 2021/12/28 06:00
CRDT- 2020/09/21 17:13
PHST- 2020/09/22 06:00 [pubmed]
PHST- 2021/12/28 06:00 [medline]
PHST- 2020/09/21 17:13 [entrez]
AID - 00124743-202201000-00019 [pii]
AID - 10.1097/RHU.0000000000001578 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2022 Jan 1;28(1):e44-e48. doi: 10.1097/RHU.0000000000001578.